TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05144646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEPENTOL® AND FARMAOLIVA® IN HEALTHY WITH INTRASUBJECT CONTROL
Description: The corresponding product (HFA -Mepentol®- or EVOO - Farmaoliva®- depending on the study group assigned) will be applied to the subject's right heel, while the contralateral, left, heel will remain as a control. To ensure that the product is completely absorbed into the skin, the subject will then be asked to remain lying face up, at an angle of 30º to the bed, for one hour. The Doppler and infrared laser probes will then be placed on each heel (on the calcaneal tuberosity), for approximately four hours. The subjects will be asked to keep their lower body immobile, but will be able to move their arms and neck gently. Average values for capillary blood flow, local temperature and tissue oxygenation will be collected at 15-minute intervals, although the first 15-minute reading, while the parameters are becoming established, will be discarded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MEPENTOL® AND FARMAOLIVA® IN PATIENTS WITH INTRASUBJECT CONTROL
Description: In the second, clinical phase, the measurement protocol will be different, although certain aspects will remain unchanged. The product in question (HFA -Mepentol®- or EVOO -Farmaoliva®- according to the randomisation group assigned) will be applied to the intervention heel (right), leaving the contralateral (left) heel as a control. In addition, every patient will receive the standard PU prevention measures described in the protocol applicable for persons at risk of this condition. The intervention will be carried out in the morning, after bathing, as is customary in acute-care hospital units. The data will be collected at 15-minute intervals, although the first interval will be discarded, as described above. This procedure will be repeated every day during hospitalisation, to assess the cumulative action of the barrier cream. Each measurement will last approximately one hour each day.
Study: NCT05057975

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sunrise
Description: Use of the Sunrise device for three nights to register mandibular movements that will be automatically analysed using artificial intelligence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polysomnography
Description: Reference protocol to diagnose OSA (in-lab or outpatient PSG)
Study: NCT05853133

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: Group E (ESP block), before the operation, the ESP block will be applied to the patients in the prone position under sedation by same anesthesiologist. ESP block will be applied bilaterally, 20 ml of %0.25 bupivacaine between the erector spinae muscle and transverse process at the 11th thoracic level. All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wound Infiltration
Description: Group W, at the end of the operation,wound infiltration will be administered under general anesthesia in supine position by same surgeon. Subfascial and subcutaneous wound infiltration is performed (20 ml of 0.25% bupivacaine each). All patients will be equipped with an IV tramadol patient-controlled analgesia (PCA) device. In the postoperative period, the patient was evaluated by another researcher who blind to the groups at the 2st and 6th, 12th and 24th hours. Visual pain scores (VAS) in rest and movement, hemodynamic values, tramadol consumption, nausea-vomiting score, ramsey sedation scale, postoperative complications will be recorded. A 40-item recovery of quality of score will be applied in the preoperative and postoperative period to evaluate the patient's quality of life.
Study: NCT05464654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 g Polynucleotide vaginal suppositories
Description: 3 g polynucleotide vaginal suppositories were administered nightly for 6 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conjugated estrogens cream 1g Tube
Description: Conjugated estrogen cream 1g was applied intravaginally on Monday, Wednesday and Friday for three months.
Study: NCT05605340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meal Delivery
Description: 10 healthy, home-delivered meals per week + brief weekly remote behavioral support
Study: NCT03921060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: treatment with denosumab every 6 months for up to 5 years
Study: NCT06477094

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stratus Nimbus Electrosurgical RF Multi-Tined Expandable Electrode
Description: Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stratus Nimbus Electrode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stryker Venom Radiofrequency Cannula
Description: Radiofrequency Ablation of Lumbar Medial Branch Nerves using the Stryker Venom Cannula
Study: NCT04757597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: RIC is a non-invasive therapy that performed by an electric autocontrol device with cuff placed on arm. RIC procedures consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on one arm. The procedure will be performed once daily for consecutive 10-14 days after enrollment.
Study: NCT04753164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-539313
Description: ACT-539313 as capsules at a strength of 100 mg, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo as identical capsules indistinguishable from ACT-539313, taken orally, b.i.d. in the morning at breakfast and in the evening at dinner, with a glass of water during the treatment period.
Study: NCT05336058

Intervention type: OTHER
Intervention: No intervention
Description: In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.

Intervention type: OTHER
Intervention: No intervention
Description: In this non-intervention study, 10ml of whole blood of enrolled subjects was collected for multi-target PCR detection of cfDNA methylation.
Study: NCT04966676

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cfDNA blood test
Description: Blood sample will be taken for cfDNA testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Antineoplastic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Antineoplastic agent

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Platinum-based Chemotherapy
Description: May include carboplatin with gemcitabine, or paclitaxel or pemetrexed
Study: NCT05163964

Intervention type: BEHAVIORAL
Intervention: Lifestyle Intervention
Description: Circadian misalignment contributes to the high glycemic outcome. To adjust meal timing earlier and avoid late-night meal eating patterns, to switch from the evening chronotype to morning chronotype possibility to reverse glucose fluctuation conditions.
Study: NCT06080529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sandbag exercise
Description: Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sandbag exercise
Description: Both arms include an exercise intervention consisted of 8 different exercises with sandbag: (1) lateral bag drag, (2) dead bag, (3) shoulder to shoulder thruster, (4) sumo DL with pull, (5) front lunge, (6) single leg RDL, (7) reverse lunge with rotation and (8) clean
Study: NCT06085690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: evidence-based intervention Plan for the Prevention of CRBSI in ICU patients
Description: On the basis of routine nursing, the evidence-based intervention Plan for the Prevention of CRBSI in ICU patients was implemented for intervention.
Study: NCT06007235

Intervention type: DEVICE
Group type: OTHER
Intervention: CACIPLIQ20
Description: CACIPLIQ20 contains RGTA heparan sulphate mimetics

Intervention type: DEVICE
Group type: OTHER
Intervention: CACIPLIQ20
Description: CACIPLIQ20 contains RGTA heparan sulphate mimetics

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Saline solution in identical spray bottles

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Saline solution in identical spray bottles
Study: NCT05154526

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Manual Therapy: High velocity-low amplitude technique

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Manual Therapy: High velocity-low amplitude technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Description: Exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Exercise program
Study: NCT05411289

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Pressures were applied on three points consecutively, firstly on two points bilaterally Hugo point (LI4) and He-7 (Shenmen), then pressure was applied on sanyinjiao (SP6).~pressure was applied gradually for 30 seconds on the above mentioned points. Then this pressure was slowly intensified to the extent that the patient felt tingling, numbness, heaviness, and strain in the surrounding area.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupressure
Description: Pressures were applied on sham points consecutively
Study: NCT05696496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: night recording
Description: The patients/controls will arrive in the evening at the Sleep Laboratory (Functional Exploration Department of the Nervous System of the Clermont-Ferrand University Hospital) to carry out complete vPSG and test the new ESM intelligent duvetdevice. A qualified technician will place the electrodes according to the procedures usually followed at the Sleep Center for vPSG recording. The ESM duvet will be placed on the patient's body as a blanket, instead of the blankets normally provided by the hospital. Patients/controls will be monitored overnight by an infrared video camera.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: night recording
Description: The patients/controls will arrive in the evening at the Sleep Laboratory (Functional Exploration Department of the Nervous System of the Clermont-Ferrand University Hospital) to carry out complete vPSG and test the new ESM intelligent duvetdevice. A qualified technician will place the electrodes according to the procedures usually followed at the Sleep Center for vPSG recording. The ESM duvet will be placed on the patient's body as a blanket, instead of the blankets normally provided by the hospital. Patients/controls will be monitored overnight by an infrared video camera.
Study: NCT05873972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: AEM A：The specialist's decision to add cetuximab to chemotherapy will be based on their own judgment~ARM B：The patient's CT imaging,genetic mutation information were input into the signature, and the FOLFOX+cetuximab regimen was selected when the output label was 1. FOLFOX+bevacizumab chemotherapy regimen was selected when the output label was 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: AEM A：The specialist's decision to add cetuximab to chemotherapy will be based on their own judgment~ARM B：The patient's CT imaging,genetic mutation information were input into the signature, and the FOLFOX+cetuximab regimen was selected when the output label was 1. FOLFOX+bevacizumab chemotherapy regimen was selected when the output label was 0
Study: NCT06294392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KEEP-CK
Description: The KEEP-CK model focuses on optimizing the role of kinship parents as the agents of positive change for children and youth. KEEP-CK groups for kinship parents are delivered by two co-group leaders for 16 weeks. Sessions are 90 minutes each week. The same group of 8-12 kinship parents attends each week. Each KEEP-CK group follows a manualized curriculum that emphasizes tailoring the content to the unique needs and cultures of the parent in the group and the youth in their care. The key parenting principles of the model include: (a) reinforce normative and prosocial behavior, (b) incentivize the behavior that parents want to promote, (c) build cooperation, (d) teach new behaviors, (e) use non-harsh effective limit setting, and (f) manage emotions while parenting. The key services connection elements of the model include: (a) parent discussions of services they are using or have used and (b) KEEP-CK group leaders share examples from a list of statewide and national services.
Study: NCT05527821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib 250mg will be taken orally once daily continuously on a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg will be intravenously administered on Day 1 of each cycle

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy
Description: 5Gy\*5F short course radiotherapy will be delivered
Study: NCT04257526

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and lifestyle advice following a positive FIT test and diagnostic colonoscopy.
Description: Participants will be recruited during CRC screening and will be included if they have a positive faecal immunochemical test (FIT) and are diagnosed with adenomas but are CRC negative during the colonoscopy. Participants receive evidence-based diet and lifestyle advice intervention with 'usual care'.
Study: NCT00863005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K201
Description: Cream

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K201
Description: Cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K201
Study: NCT05727657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satralizumab
Description: 120mg subcutaneous Day 0 and Day 14
Study: NCT05813704

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary Crossing System of Shanghai MicroPort Rhythm
Description: The mechanical vibration generated by the Coronary Crossing System through the piezoelectric effect is amplified and transmitted to the distal end of the guidewire to achieve high-frequency vibration at the tip of the guidewire, and then achieve efficient and safe penetration of the fibrous cap of the CTO.
Study: NCT05585814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is given orally at 1500mg / m² twice a day from day1-14 every 3weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is given by intravenous infusion at 200mg / m2 on Day 1 every 3 weeks for 3cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is given intravenously at 10mg/kg on day 1 every 3 weeks for 3 cycles
Study: NCT06051344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: . Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: . Total 92 primary knee OA patients will be enrolled by following the inclusion criteria of ages 50 years and above with primary knee OA informed written consent. Then randomization will be done into group A and group B following a randomization table, each consist of 46 patients. Consecutive sampling technique will be followed. Primary knee OA will be diagnosed on the basis of ACR clinical and radiological criteria. Relevant laboratory investigations will be done. Baseline pain status will be measured by Bangla version of Western Ontario and McMaster Universities Osteoarthritis index (WOMAC), visual analog scale (VAS) and numerical rating scale (NRS) and quality of life will be measure by European quality of life scale (EQ-5D-5L). Then one group will receive single infusion of 5mg zoledronic acid and another group will receive the placebo
Study: NCT05882149

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Single strain probiotic
Description: Sugar-free chewing gum with single strain probiotic and zinc.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar-free chewing gum.~The dosage will be 2 chewing a day, served at the same time and chewed for 6 minutes outside meals (for example 2h after breakfast or lunch).
Study: NCT06440876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music and Imagery
Description: See music and imagery arm description.
Study: NCT05585814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is given intravenously at 200 mg on day 1 every 3 weeks for 3 cycles
Study: NCT05193474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated palliative care
Description: shared decision making with patient, and timely integrated palliative care according to patient's preference
Study: NCT06395441

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American Ginseng
Description: Given PO
Study: NCT06528392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Description: Efgartigiomd-hyaluroidase (EFG) is a neonatal Fc receptor (FcRn) inhibitor, which blocks the recycling of Immunoglobulin G (IgG), including pathogenic IgG
Study: NCT06395441

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06410755

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring system using a insole-type gait analyzer
Description: The researcher provides feedback over the phone once a week in accordance with the subjects' amount of exercise and walking level collected only to the experimental group using the insole-type gait analysis system. Check the stability of data collection, and if an abnormality occurs, take action and record it by phone or in person
Study: NCT05874882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resveratrol mouthwash as adjunct to scaling and root planing in periodontitis patients
Description: patients with periodontitis will receive scaling and rootplaning and a resveratrol mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine mouthwash as adjunct to scaling and root planing in periodontitis patients
Description: patients with periodontitis will receive scaling and rootplaning and a chlorhexidine mouthwash twice daily for 4 weeks. saliva will be collected at the 1st visit and after one month then biochemical analysis for inflammatory biomarker will be done. periodontal parameters also will be evaluated at the 1st visit and after 1 month
Study: NCT04579900

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopy and duodenal biopsy and sampling
Description: All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy and duodenal biopsy and sampling
Description: All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples
Study: NCT05184452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (5mg/kg, IV)
Description: 5 mg/kg to be administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (20mg/kg, IV)
Description: 20 mg/kg to be administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (20mg/kg, IV)
Description: 20 mg/kg to be administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (20mg/kg, SC)
Description: 20 mg/kg to be administered via SC infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (20mg/kg, SC)
Description: 20 mg/kg to be administered via SC infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (40mg/kg, IV)
Description: 40 mg/kg to be administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (40mg/kg, IV)
Description: 40 mg/kg to be administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (40mg/kg, SC)
Description: 40 mg/kg to be administered via SC infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (1.4g, IV)
Description: 1.4gram to be administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PGDM1400LS (1.4g, SC)
Description: 1.4gram to be administered via SC infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (20mg/kg, IV)
Description: VRC07-523LS 20mg/kg administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRC07-523LS (20mg/kg, SC)
Description: VRC07-523LS 20mg/kg administered via SC infusion